We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
+14.38%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$810M
AUM Growth
+$268M
Cap. Flow
+$286M
Cap. Flow %
35.27%
Top 10 Hldgs %
71.5%
Holding
51
New
7
Increased
2
Reduced
11
Closed
1

Top Buys

Rank Stock Value
1
LENZ
LENZ Therapeutics
LENZ
+$185M
2
CNTA
Centessa Pharmaceuticals
CNTA
+$36.1M
3
RAIN
Rain Oncology Inc. Common Stock
RAIN
+$28.7M
4
RXRX icon
Recursion Pharmaceuticals
RXRX
+$23M
5
JANX icon
Janux Therapeutics
JANX
+$13.5M

Top Sells

Rank Stock Value
1
CVAC
CureVac
CVAC
+$8.72M
2
ACRS icon
Aclaris Therapeutics
ACRS
+$5.19M
3
TERN
Terns Pharmaceuticals
TERN
+$3.55M
4
VTGN icon
VistaGen Therapeutics
VTGN
+$2.71M
5
KRON
Kronos Bio
KRON
+$2.23M

Sector Composition

Rank Sector Weight
1 Healthcare 92.52%
2 Financials 1.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CVAC
51
DELISTED
CureVac
CVAC
– –
-95,318
Closed -$8.72M
1 2
3

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
GSIS
Global Strategic Investment Solutions Scottsdale, Arizona $1.03B AUM 16.75% 1-Year Est. Return
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return
MSA
Mason Street Advisors Milwaukee, Wisconsin $1.02B AUM 8.35% 1-Year Est. Return

Samsara BioCapital's Q2 2021 Portfolio in Review

As of Q2 2021, Samsara BioCapital held 51 positions worth $810M, up 49% from $542M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Samsara BioCapital deployed $286M of net new capital in Q2 2021, opening 7 new positions and adding to 2 existing holdings. Its largest new stake was LENZ Therapeutics: 1,061,660 shares worth $228M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 90% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Aclaris Therapeutics, an estimated $5.19M trimmed.

  • Samsara BioCapital's largest Q2 2021 buy was LENZ Therapeutics: 1,061,660 shares worth $228M.
  • Samsara BioCapital added most to Instil Bio in Q2 2021, an estimated $11M increase.
  • Samsara BioCapital's biggest Q2 2021 reduction was Aclaris Therapeutics, cutting an estimated $5.19M.
  • Samsara BioCapital fully exited CureVac in Q2 2021, selling an estimated $8.72M.
  • Samsara BioCapital's ten largest holdings make up 72% of its $810M portfolio in Q2 2021.
  • Samsara BioCapital opened 7 new positions and closed 1 in Q2 2021.
  • Samsara BioCapital's portfolio value rose 49% quarter-over-quarter to $810M.

Based on Samsara BioCapital's 13F filing for Q2 2021, filed 17 Aug 2021.